Avingtrans Strengthens Nuclear and Infrastructure Positions with Major Contract Wins

Avingtrans trading update: steady profits, fresh nuclear orders and one awkward legacy issue

Avingtrans has used this trading update to deliver a pretty balanced message. On the positive side, profit for the year ended 31 May 2026 is expected to be in line with market expectations, and the group has landed several strategically important contract wins in nuclear and infrastructure. On the less cheerful side, it has also flagged a repayment issue linked to historic US Covid-era loans.

For retail investors, that mix matters. This is not a blowout upgrade, but it is also not a profit warning. Instead, it reads like a business that is executing sensibly in its core markets, while dealing with one messy but apparently contained historical problem.

Key Avingtrans numbers from the FY26 trading update

Item	Figure
FY26 profit	In line with market expectations
South Korea nuclear spare parts contract	US$4 million
First BWX Technologies order in the US	US$1.8 million
HS2 doors contract	£2 million
Total HS2 contract award value for Booth	Over £50 million
Data centre cumulative revenues	Approximately £4 million
Data centre opportunity pipeline	Around £40 million
PPP Second Draw loan principal to repay	Approximately US$3.1 million
PPP total with interest and penalties	Approximately US$5.0 million
Expected PPP repayment period	Approximately 24 months
Scientific Magnetics quantum computing orders	Over 30 orders

Nuclear contract wins show Avingtrans is deepening its moat

The standout feature here is the strength of the Advanced Engineering Systems division, or AES. Avingtrans says it is entering the new financial year with a strong order book and is still winning orders after the year end. That is exactly what investors want to hear in industrial businesses, because order books give some visibility over future revenue.

The South Korea contract is a good example. Avingtrans secured a further US$4 million contract with KHNP to supply spare parts for Westinghouse-designed Pressurised Water Reactors at Hanbit Nuclear Power Station. In plain English, this is aftermarket work for critical nuclear infrastructure – the sort of business that tends to be specialised, sticky and difficult for rivals to dislodge.

Even more interesting, in my view, is the first order from BWX Technologies in the United States, worth US$1.8 million. Management is clearly highlighting this because it follows investment to access the highly regulated US nuclear defence market. First orders matter because they validate the capability, the certifications and the customer relationships needed to win more.

That does not mean investors should get carried away and annualise one contract into a giant growth story overnight. But it does suggest Hayward Tyler is starting to convert a strategic market-entry effort into actual revenue. That is a meaningful step forward.

HS2 and UK infrastructure contracts add dependable engineering revenue

Avingtrans also announced a £2 million contract to supply high-security and fire protection doors for the HS2 N1 and N2 tunnel service shafts and headhouses. On its own, £2 million is not huge in the context of a diversified group, but the bigger point is continuity.

This award takes Booth’s total contract award value on HS2 to over £50 million. That tells you Booth has become a trusted supplier on a major UK infrastructure programme. Trusted supplier status tends to matter in safety-critical projects, where procurement teams are usually more interested in proven delivery than gambling on the cheapest new name.

For investors, this part of the update supports the idea that Avingtrans has good exposure to long-cycle infrastructure spending. It is not flashy, but it can be valuable.

Data centre growth gives Avingtrans a useful new angle beyond nuclear

One of the more intriguing lines in the statement is the progress in data centres. Avingtrans says Ormandy is expected to ship its tenth data centre solution during the first quarter of FY27. Cumulative revenues from this market have now reached approximately £4 million, while the identified opportunity pipeline has grown to around £40 million.

That pipeline figure is the real attention-grabber. A pipeline is not the same as contracted revenue, so investors should be careful not to treat it as banked sales. Still, a £40 million opportunity set from an emerging market for the group suggests management is finding a genuine growth lane outside its traditional areas.

Why does that matter? Because data centres are a major investment theme and they need cooling, HVAC and related infrastructure. Avingtrans is not trying to become a tech stock, but it does not need to. It simply needs to prove it can supply mission-critical equipment into a market that is expanding fast.

Medical and imaging progress is real, but commercial revenues are still lagging

The Medical & Industrial Imaging division, or MII, produced a more mixed picture. The big positive is regulatory progress. The Adaptix Ortho350 won both FDA 510(k) clearance in the USA and CE certification for the UK and Europe.

That is an important milestone because regulatory clearance is often the gatekeeper between promising technology and actual sales. Without it, commercialisation remains mostly theoretical.

However, the company also admits revenues for MII were lower than intended, mainly because of timing in receiving those regulatory clearances. That is a fair explanation, but it still means the division is behind prior hopes on revenue generation.

Management says it is now focused on building its UK and US reseller network, with a number of distributors signed up and first use reimbursement data being generated. That sounds encouraging, but the RNS does not disclose how many distributors, how much revenue, or how quickly this will scale. So investors have progress signals, but not yet hard proof of commercial traction.

Elsewhere in MII, Adaptix signed its first material contract in Non Destructive Testing, the veterinary product continued to make steady progress, and Scientific Magnetics has now had over 30 orders for magnet and cryogenics packages for quantum computing applications. Meanwhile, Magnetica still does not have clearance to sell its compact MRI product in the USA. That remains a clear hold-up.

The PPP repayment issue is the main negative investors need to watch

The least attractive part of the update is the Paycheck Protection Program issue. Avingtrans says its US businesses received loans during the pandemic which were later forgiven, but it has since emerged that the businesses did not qualify for the Second Draw loans due to complex eligibility rules around employee-count limits for foreign-owned groups with US subsidiaries.

The US Government has required repayment of the Second Draw loans. The principal amount is approximately US$3.1 million, and with interest and penalties the total is expected to be approximately US$5.0 million. Repayment terms are still under discussion, but are currently expected to be spread over approximately 24 months.

That is plainly a negative. A US$5.0 million cash outflow is not trivial, and investors should never ignore regulatory or compliance-related issues, even when management labels them historical.

That said, the company has chosen not to contest the matter and says this is a one-off historical issue with no impact on current operations or strategy. Based on the RNS alone, that seems credible enough, but it will still be worth watching how the final settlement is structured and whether any further knock-on effects emerge. For now, it looks like a painful cleanup item rather than a live operational threat.

What this Avingtrans update means for shareholders ahead of results

Overall, I would call this a cautiously positive trading update. The core engineering businesses appear to be performing well, profit is in line with expectations, the nuclear order momentum looks strong, and there are signs of useful diversification into data centres. Those are all solid ingredients.

The MII division remains more of a medium-term story than a near-term earnings engine, despite the welcome regulatory wins. And the PPP repayment issue is an obvious drag on sentiment, even if it seems ring-fenced and manageable over approximately 24 months.

The bigger investment case still looks centred on Avingtrans being a specialist engineering group with strong positions in attractive, hard-to-enter markets. If the nuclear and infrastructure momentum continues, and if newer growth areas like data centres and imaging start converting more clearly into revenue, there could be more to come. But for now, this update is more about steady progress than dramatic transformation.

Next date for Avingtrans investors to watch

Avingtrans expects to publish its audited results for the year ended 31 May 2026 on 30 September 2026. That is when investors should expect more detail on performance, cash, divisional profitability and, ideally, a clearer picture of how much these contract wins are feeding into future growth.

In short, the message today is simple enough: the engine is running fine, the order book looks healthy, but there is one old bill to settle.